drugset / Trial / NCT05142696
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
RandomizedSequentialOpen-labelTreatment
Summary
This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.
Timeline
- Start
- 2022-07-13
- Primary completion
- 2028-03-07
- Completion
- 2028-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [177Lu]Lu-DOTA-TATE | Other / unclassified | 3700 mbq | — |
| Subject | [177Lu]Lu-DOTA-TATE | Other / unclassified | 5550 mbq | — |
| Subject | [177Lu]Lu-DOTA-TATE | Other / unclassified | 7400 mbq | — |
| Subject | [177Lu]Lu-DOTA-TATE | Other / unclassified | 9250 mbq | — |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | — |
| Background | [68Ga]Ga-DOTA-TATE | Diagnostic / imaging agent | 2 mbq/kg | — |